Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

Expected outcomes

• Projects should contribute to all of the expected outcomes.
• For each outcome (EO1 to EO5), name who will use or adopt your results (a specific group, not “industry” or “society”), how they get them, and the indicator that shows the change, with baseline, target and date.
• Use the topic's own words for each outcome, so the evaluator can tick it off.

What the scope asks for

Evaluators check the proposal against these sentences of the scope. Answer each one visibly, in the call's own words.

• “Proposals should address all of the following:.”
• “The focus should be on affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines that benefit cancer patients.”
• “The requested innovative solutions for healthcare systems in the areas of affordable cancer technologies, cancer medical devices, or cancer medicines should be clinically validated, piloted or upscaled by the participating procurers in at least five different countries across the EU Member States and Associated Countries.”
• “Continuous dialogue between the demand and supply side is required for the success of pre-commercial procurement.”
• “Therefore the effective involvement of end-users (e.g. academia, clinical teams, cancer patients and their caregivers/families, cancer patient representatives, local or regional medical services, hospitals, production facilities) must be considered in the proposal.”
• “To stimulate dialogue with the supply side, procurers are required to organise an open-market consultation before launching the procurement and to promote the call for tenders widely across Europe to potentially interested suppliers.”
• “Procurers should declare in the proposal their interest to purchase at least one solution resulting from the PCP in case the PCP delivers successful solutions and indicate whether they will (1) procure the solution(s) as part of the PCP or (2) in a separate follow-up procurement after the PCP.”
• “In the second case, the procurers must include in the proposal a deliverable that prepares the follow-up procurement to purchase successful solution(s) after the PCP.”
• “Activities covered should support national healthcare systems and mobilise technical assistance and/or capacity building to other procurers beyond the project to mainstream PCP implementation and to remove obstacles for introducing the innovative solutions for the benefit of cancer patients to be procured into the market.”

Conditions that shape the proposal

• Other Eligibility Conditions: “The specific conditions for actions with PCP/PPI procurements in section H of the General Annexes apply to grants funded under this topic.”
• Legal and financial set-up of the grants: “The specific conditions are described in General Annex H.”
• Legal and financial set-up of the grants: “PCP procurement costs are eligible.”

Impact pathway and traps

• Users or citizens are part of the scope. Show how they take part in the design and testing, not only that they are informed.
• The scope expects pilots or demonstration. Name the sites, the partners who run them and what is measured there.
• Market uptake is part of the scope. Evaluators look for a credible route to market with named first adopters.
• Keep outputs, outcomes and impacts apart: what you deliver, what changes when others use it, and the long-term effect.
• Link your outcomes to the destination's expected impacts in the Work Programme. Destination impacts are long-term effects, not project deliverables.
• Name the barriers outside the project (regulation, markets, user behaviour) that could block uptake, and what you will do if they do.
• Section 2.3 (the summary canvas) is optional on this call; the old split into scientific, economic and societal impact is no longer required.